Novo Nordisk's Legal Gambit Backfires as Investors Weigh the Cost of Combat
Published on 08/16/2026 at 13:22 | Redaktion boerse-global.de
The arithmetic of the courtroom has not been kind to Novo Nordisk. Since filing its lawsuit against Eli Lilly in late July, the Danish drugmaker's shares have shed 6 percent, while its US rival has gained nearly 4 percent over the same stretch — a divergence that underscores just how differently Wall Street has read the legal escalation.
CEO Mike Doustdar, however, remains unapologetic about taking the fight to New Jersey federal court. "Competition must be tough, but I think competition must also be fair," he said on Thursday, defending the decision to sue Eli Lilly and its subsidiary Lilly USA over allegedly misleading advertising tied to direct-to-consumer campaigns for their competing GLP-1 weight-loss drugs.
A Stock Already on the Back Foot
The lawsuit landed in a period when Novo Nordisk could ill afford additional headwinds. The stock closed Friday at EUR 39.40, down 2.6 percent on the day, leaving it 3.9 percent lower on the week and 11 percent in the red over the past month. The shares now trade roughly 28 percent below their 52-week high of EUR 54.86, reached back in January, and sit about 4.7 percent beneath their 50-day moving average of EUR 41.34 — a technical signal that the near-term downtrend has yet to find a floor.
That erosion predates the litigation. The company's first-half results, published around two weeks before the suit, came with a revised full-year outlook calling for anywhere between flat growth and a 6 percent decline in both adjusted revenue and operating profit. Disappointing trial data for the cardiovascular candidate Ziltivekimab added to the gloom, leaving the stock vulnerable when the analyst downgrades began rolling in.
Berenberg was the first to move, cutting its rating on Tuesday from "Buy" to "Hold." The bank's previous bullish thesis had hinged on the upside potential of the oral Wegovy pill — potential that materialized in the first half of 2026 but now faces what Berenberg expects to be intensifying competition in the oral weight-loss segment during the second half. BMO Capital Markets issued a Hold rating of its own the same day.
Beyond the Courtroom: A Pivot in Marketing and Pipeline
Amid the legal noise, Novo Nordisk has been quietly reshuffling its US commercial operations. On Friday, the company appointed Omnicom as its new agency for marketing Ozempic and Wegovy, ending a four-year relationship with WPP. The switch comes as the company juggles legal, regulatory, and competitive pressures simultaneously.
There was brighter news on the regulatory front. The European Commission granted marketing authorization for the once-daily oral Wegovy tablet at a 25-milligram semaglutide dose for weight management in adults, with a German market launch penciled in for the third quarter of 2026. The approval adds an oral alternative to the established injectable versions — a format that could appeal to patients wary of needles.
While Novo Nordisk navigates regulatory approvals and competitive pressures, workplace compliance brings its own set of legal obligations. UK employers face similar scrutiny when it comes to documenting workplace hazards — and a free toolkit with 41 ready-to-use templates can help you stay ahead of inspections. Download the free Risk Assessment Toolkit
Yet the oral pill's commercial trajectory has so far been underwhelming. Second-quarter sales of the oral Wegovy formulation came in at DKK 3.22 billion, just shy of the DKK 3.27 billion analysts had penciled in — a sign that the flagship growth driver has not yet gathered the momentum the market expected.
Small Wins, Persistent Pressure
Elsewhere in the pipeline, Novo Nordisk began the nationwide US rollout of Awiqli on August 11, marking the first once-weekly basal insulin for adults with type 2 diabetes. A day earlier, the company unveiled a strategic collaboration with Amazon Web Services to deploy generative AI for drug discovery and trial design from a joint innovation hub in London. The company also secured a Dutch court injunction banning the sale of unapproved compounded semaglutide nasal sprays — a victory for both intellectual property protection and patient safety.
These developments, however, have done little to shift the market's focus. The Relative Strength Index sits at 40.6, suggesting persistent weakness rather than oversold conditions. With a market capitalization of EUR 174.27 billion, Novo Nordisk remains a heavyweight — but the cost of defending its turf in the obesity market, both in court and in the clinic, is becoming increasingly visible in the share price.
Just as drugmakers must defend their regulatory standing, UK businesses face their own compliance pressures — particularly around hazardous substances. Over 37,000 companies use a free COSHH toolkit with 43 customisable templates to meet their legal duties for assessing dangerous substances. Get the free COSHH Toolkit
The next opportunity for a reassessment comes on November 4, when the company reports third-quarter results. Until then, the legal proceedings and the competitive dynamics in oral GLP-1 therapies are likely to keep the stock on a short leash, with investors weighing whether the company's aggressive defense of its franchise is a sign of strength — or a symptom of mounting pressure.
